Skip to main content
Top
Published in: Infection 1/2018

01-02-2018 | Original Paper

Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy

Authors: Evangelista Sagnelli, Tommaso Stroffolini, Caterina Sagnelli, Mario Pirisi, Sergio Babudieri, Guido Colloredo, Maurizio Russello, Nicola Coppola, Giovanni Battista Gaeta, Bruno Cacopardo, Massimo De Luca, Piero Luigi Almasio, on behalf of EPACRON study group

Published in: Infection | Issue 1/2018

Login to get access

Abstract

Background

Gender differences in chronic liver disease (CLD) have been partially investigated. To extend the present knowledge, we evaluated 12,263 patients with CLD enrolled in two national surveys (9997 in 2001 and 2557 in 2014).

Methods

The two surveys prospectively recruited patients aged ≥ 18 referring to Italian liver units throughout the country using a similar clinical approach and analytical methods.

Results

The overall male to female ratio (M/F) was 1.4 (7138/5124). Compared with females, males were significantly more likely to be younger (52.9 vs. 58.7 yrs.), with HBV infection alone (13.2% vs. 9.2%) and with alcoholic liver disease alone (11.4% vs. 6.9%), but less likely to show HCV infection alone (48.0% vs. 67.9%). A male preponderance was observed in HBV-related cases (1.99) and in alcoholic-related cases (2.3), a preponderance observed both in the 2001 and in 2014 cases. In HCV-related cases, however, females predominated in 2001 (M/F 0.9) and males in 2014 (M/F 1.5).The rate of cirrhosis in alcohol-related etiology was close to 36% in both genders, a finding much higher than that observed for both sexes in HBV and HCV etiologies.Both males and females enrolled in 2014 were older (p < 0.001) and with a higher rate of cirrhosis and/or HCC (p < 0.001) than those investigated in 2001. There was a remarkable increase over time in the proportion of male abstainers (36.7% in 2001 and 64.3% in 2014).

Conclusion

This study highlights important inter- and intra-gender differences in the characteristics and etiological factors of patients with CLD in Italy.
Literature
1.
go back to reference Blumberg BS, Sutnick AI, London WT, Melartin L. Sex distribution of Australia antigen. Arch Intern Med. 1972;130:227–31 (PMID:4262014).CrossRefPubMed Blumberg BS, Sutnick AI, London WT, Melartin L. Sex distribution of Australia antigen. Arch Intern Med. 1972;130:227–31 (PMID:4262014).CrossRefPubMed
2.
go back to reference McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med. 1990;150:1051–4.CrossRefPubMed McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med. 1990;150:1051–4.CrossRefPubMed
3.
go back to reference Chen DS. Natural history of chronic hepatitis B virus infection: new light on an old story. J Gastroenterol Hepatol. 1993;8:470–5.CrossRefPubMed Chen DS. Natural history of chronic hepatitis B virus infection: new light on an old story. J Gastroenterol Hepatol. 1993;8:470–5.CrossRefPubMed
4.
go back to reference Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 2001;34:730–9.CrossRefPubMed Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 2001;34:730–9.CrossRefPubMed
5.
go back to reference Lee CM, Lu SN, Changchien CS, Yeh CT, Hsu TT, Tang JH, et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer. 1999;86:1143–50.CrossRefPubMed Lee CM, Lu SN, Changchien CS, Yeh CT, Hsu TT, Tang JH, et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer. 1999;86:1143–50.CrossRefPubMed
6.
go back to reference Evans AA, Chen G, Ross EA, Shen FM, Lin WY, London WT. Eight-year follow-up of the 90,000-person Haimen City cohort: i. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomark Prev. 2002;11:369–76. Evans AA, Chen G, Ross EA, Shen FM, Lin WY, London WT. Eight-year follow-up of the 90,000-person Haimen City cohort: i. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomark Prev. 2002;11:369–76.
7.
go back to reference Chang MH, Shau WY, Chen CJ, Wu TC, Kong MS, Liang DC, et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. J Am Med Ass. 2000;284:3040–2.CrossRef Chang MH, Shau WY, Chen CJ, Wu TC, Kong MS, Liang DC, et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. J Am Med Ass. 2000;284:3040–2.CrossRef
9.
go back to reference Stroffolini T. The changing pattern of hepatitis B virus infection over the past three decades in Italy. Dig Liver Dis. 2005;37:622–7.CrossRefPubMed Stroffolini T. The changing pattern of hepatitis B virus infection over the past three decades in Italy. Dig Liver Dis. 2005;37:622–7.CrossRefPubMed
10.
go back to reference Boix R, Cano R, Gallego P, Vallejo F, Fernández-Cuenca R, Noguer I, Larrauri A. Hepatitis C hospitalizations in Spain, 2004–2013: a retrospective epidemiological study. BMC Health Serv Res. 2017;17:461.CrossRefPubMedPubMedCentral Boix R, Cano R, Gallego P, Vallejo F, Fernández-Cuenca R, Noguer I, Larrauri A. Hepatitis C hospitalizations in Spain, 2004–2013: a retrospective epidemiological study. BMC Health Serv Res. 2017;17:461.CrossRefPubMedPubMedCentral
11.
go back to reference Sanna A, Le Strat Y, Roudot-Thoraval F, Deuffic Burban S, Carrieri P, Delarocque-Astagneau E, Larsen C. Severe liver disease related to chronic hepatitis C virus infection in treatment-naïve patients: epidemiological characteristics and associated factors at first expert centre visit, France, 2000 to 2007 and 2010 to 2014. Euro Surveill. 2017;22:30582.CrossRefPubMedPubMedCentral Sanna A, Le Strat Y, Roudot-Thoraval F, Deuffic Burban S, Carrieri P, Delarocque-Astagneau E, Larsen C. Severe liver disease related to chronic hepatitis C virus infection in treatment-naïve patients: epidemiological characteristics and associated factors at first expert centre visit, France, 2000 to 2007 and 2010 to 2014. Euro Surveill. 2017;22:30582.CrossRefPubMedPubMedCentral
12.
go back to reference Shimizu I, Kohno N, Tamaki K, et al. Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection. World J Gastroenterol. 2007;13:4295–305.CrossRefPubMedPubMedCentral Shimizu I, Kohno N, Tamaki K, et al. Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection. World J Gastroenterol. 2007;13:4295–305.CrossRefPubMedPubMedCentral
13.
go back to reference Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–14.CrossRefPubMed Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–14.CrossRefPubMed
14.
go back to reference Rantala M, van de Laar MJ. Surveillance and epidemiology of hepatitis B and C in Europe: a review. Euro Surveill. 2008;13:18880.CrossRefPubMed Rantala M, van de Laar MJ. Surveillance and epidemiology of hepatitis B and C in Europe: a review. Euro Surveill. 2008;13:18880.CrossRefPubMed
15.
go back to reference Giusti G, Ruggiero G, Galanti B, Piccinino F, Sagnelli E, Gallo C. Chronic active hepatitis in Italy: a multicentric study on clinic and laboratory data of 1,154 cases. Hepatogastroenterology. 1983;30:126–30. Giusti G, Ruggiero G, Galanti B, Piccinino F, Sagnelli E, Gallo C. Chronic active hepatitis in Italy: a multicentric study on clinic and laboratory data of 1,154 cases. Hepatogastroenterology. 1983;30:126–30.
16.
go back to reference Sagnelli E, Stroffolini T, Mele A, Almasio P, Coppola N, Ferrigno L, et al. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. J Med Virol. 2005;75:522–7.CrossRefPubMed Sagnelli E, Stroffolini T, Mele A, Almasio P, Coppola N, Ferrigno L, et al. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. J Med Virol. 2005;75:522–7.CrossRefPubMed
17.
go back to reference Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349(9055):825–32.CrossRefPubMed Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349(9055):825–32.CrossRefPubMed
19.
go back to reference Ashcroft GS, Dodsworth J, van Boxtel E, Tarnuzzer RW, Horan MA, Schultz GS, et al. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-beta1 levels. Nat Med. 1997;3:1209–15.CrossRefPubMed Ashcroft GS, Dodsworth J, van Boxtel E, Tarnuzzer RW, Horan MA, Schultz GS, et al. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-beta1 levels. Nat Med. 1997;3:1209–15.CrossRefPubMed
21.
go back to reference Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999;340:1228–12333 (PMID:10210705).CrossRefPubMed Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999;340:1228–12333 (PMID:10210705).CrossRefPubMed
22.
go back to reference Wiese M, Grüngreiff K, Güthoff W, Lafrenz M, Oesen U, Porst H, et al. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany–a 25-year multicenter study. J Hepatol. 2005;43:590–8.CrossRefPubMed Wiese M, Grüngreiff K, Güthoff W, Lafrenz M, Oesen U, Porst H, et al. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany–a 25-year multicenter study. J Hepatol. 2005;43:590–8.CrossRefPubMed
26.
go back to reference Sagnelli E, Stroffolini T, Mele A, Imparato M, Almasio PL, Italian Hospitals’ Collaborating Group. Chronic hepatitis B in Italy: new features of an old disease—approaching the universal prevalence of hepatitis B e antigen negative cases and the eradication of hepatitis D infection. Clin Infect Dis. 2008;46:110–3.CrossRefPubMed Sagnelli E, Stroffolini T, Mele A, Imparato M, Almasio PL, Italian Hospitals’ Collaborating Group. Chronic hepatitis B in Italy: new features of an old disease—approaching the universal prevalence of hepatitis B e antigen negative cases and the eradication of hepatitis D infection. Clin Infect Dis. 2008;46:110–3.CrossRefPubMed
27.
go back to reference Sagnelli E, Stroffolini T, Mele A, Imparato M, Sagnelli C, Coppola N, et al. Impact of comorbidities on the severity of chronic hepatitis B at presentation. World J of Gastroenterol. 2012;18:1616–21.CrossRef Sagnelli E, Stroffolini T, Mele A, Imparato M, Sagnelli C, Coppola N, et al. Impact of comorbidities on the severity of chronic hepatitis B at presentation. World J of Gastroenterol. 2012;18:1616–21.CrossRef
28.
go back to reference Stroffolini T, Sagnelli E, Mariano A, Craxí A, Almasio P, Italian Hospitals Collaborating Group. Characteristics of HCV positive subjects referring to hospitals in Italy: a multicentre prevalence study on 6,999 cases. J Viral Hepat. 2006;13:351–4.CrossRefPubMed Stroffolini T, Sagnelli E, Mariano A, Craxí A, Almasio P, Italian Hospitals Collaborating Group. Characteristics of HCV positive subjects referring to hospitals in Italy: a multicentre prevalence study on 6,999 cases. J Viral Hepat. 2006;13:351–4.CrossRefPubMed
30.
go back to reference Taal BG, Schalm SW, ten Kate FW, Hermans J, Geertzen RG, Feltkamp BE. Clinical diagnosis of primary biliary cirrhosis: a classification based on major and minor criteria. Hepatogastroenterology. 1983;30:178–82.PubMed Taal BG, Schalm SW, ten Kate FW, Hermans J, Geertzen RG, Feltkamp BE. Clinical diagnosis of primary biliary cirrhosis: a classification based on major and minor criteria. Hepatogastroenterology. 1983;30:178–82.PubMed
31.
go back to reference Alvarez F, Berg PA, Bianchi FB, Burroughs AK, Cancado EL, Chapman RW, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J of Hepatol. 1999;31:929–38.CrossRef Alvarez F, Berg PA, Bianchi FB, Burroughs AK, Cancado EL, Chapman RW, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J of Hepatol. 1999;31:929–38.CrossRef
32.
go back to reference Adams PC, Chakrabarti S. Genotypic/phenotypic correlations in genetic hemochromatosis: evolution of diagnostic criteria. Gastroenterology. 1998;114:319–23.CrossRefPubMed Adams PC, Chakrabarti S. Genotypic/phenotypic correlations in genetic hemochromatosis: evolution of diagnostic criteria. Gastroenterology. 1998;114:319–23.CrossRefPubMed
33.
go back to reference Ferenci P, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int. 2003;23:139–42.CrossRefPubMed Ferenci P, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int. 2003;23:139–42.CrossRefPubMed
34.
go back to reference Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002;17:S186–90.CrossRefPubMed Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002;17:S186–90.CrossRefPubMed
35.
go back to reference Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–30.CrossRefPubMed Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–30.CrossRefPubMed
36.
go back to reference Gaiani S, Gramantieri L, Venturoli N, Piscaglia F, Siringo S, D’Errico A, et al. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol. 1997;27:979–85.CrossRefPubMed Gaiani S, Gramantieri L, Venturoli N, Piscaglia F, Siringo S, D’Errico A, et al. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol. 1997;27:979–85.CrossRefPubMed
37.
go back to reference Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–9.CrossRefPubMed Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–9.CrossRefPubMed
38.
go back to reference Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–93.CrossRefPubMed Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–93.CrossRefPubMed
39.
go back to reference Gamal S, Khaled Z. Ishak versus METAVIR: terminology, convertibility and correlation with laboratory changes in chronic hepatitis C, liver biopsy. In: Takahashi H, editor. InTech 2011. Chap 10. https://doi.org/10.5772/20110. Gamal S, Khaled Z. Ishak versus METAVIR: terminology, convertibility and correlation with laboratory changes in chronic hepatitis C, liver biopsy. In: Takahashi H, editor. InTech 2011. Chap 10. https://​doi.​org/​10.​5772/​20110.
40.
go back to reference Sagnelli E, Stroffolini T, Mele A, Imparato M, Sagnelli C, Coppola N, et al. Impact of comorbidities on the severity of chronic hepatitis B at presentation. World J Gastroenterol. 2012;18:1616–21.CrossRefPubMedPubMedCentral Sagnelli E, Stroffolini T, Mele A, Imparato M, Sagnelli C, Coppola N, et al. Impact of comorbidities on the severity of chronic hepatitis B at presentation. World J Gastroenterol. 2012;18:1616–21.CrossRefPubMedPubMedCentral
42.
go back to reference Brusaferro S, Barbone F, Andrian P, Brianti G, Ciccone L, Furlan A, et al. A study on the role of the family and other risk factors in HCV transmission. Eur J Epidemiol. 1999;15:125–32.CrossRefPubMed Brusaferro S, Barbone F, Andrian P, Brianti G, Ciccone L, Furlan A, et al. A study on the role of the family and other risk factors in HCV transmission. Eur J Epidemiol. 1999;15:125–32.CrossRefPubMed
43.
go back to reference Gheorghe L, Csiki IE, Iacob S, Gheorghe C, Smira G, Regep L. The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: a nationwide survey 2006–2008. Gastrointest Liver Dis. 2010;19:373–9. Gheorghe L, Csiki IE, Iacob S, Gheorghe C, Smira G, Regep L. The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: a nationwide survey 2006–2008. Gastrointest Liver Dis. 2010;19:373–9.
44.
go back to reference Pendino GM, Mariano A, Surace P, Caserta CA, Fiorillo MT, Amante A, et al. Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. Hepatology. 2005;41:1151–9.CrossRefPubMed Pendino GM, Mariano A, Surace P, Caserta CA, Fiorillo MT, Amante A, et al. Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. Hepatology. 2005;41:1151–9.CrossRefPubMed
45.
go back to reference Ulitzky L, Lafer MM, KuKuruga MA, Silberstein E, Cehan N, Taylor DR. A new signaling pathway for HCV inhibition by estrogen: gPR30 activation leads to cleavage of occludin by MMP-9. PLoS ONE. 2016;11:e0145212.CrossRefPubMedPubMedCentral Ulitzky L, Lafer MM, KuKuruga MA, Silberstein E, Cehan N, Taylor DR. A new signaling pathway for HCV inhibition by estrogen: gPR30 activation leads to cleavage of occludin by MMP-9. PLoS ONE. 2016;11:e0145212.CrossRefPubMedPubMedCentral
46.
go back to reference Di Martino V, Lebray P, Myers RP, Pannier E, Paradis V, Charlotte F, et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefits of estrogen exposure. Hepatology. 2004;40:1426–33.CrossRefPubMed Di Martino V, Lebray P, Myers RP, Pannier E, Paradis V, Charlotte F, et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefits of estrogen exposure. Hepatology. 2004;40:1426–33.CrossRefPubMed
47.
go back to reference Zheng B, Zhu YJ, Wang HY, Chen L. Gender disparity in hepatocellular carcinoma (HCC): multiple underlying mechanisms. Sci China Life Sci. 2017;60:75–584. Zheng B, Zhu YJ, Wang HY, Chen L. Gender disparity in hepatocellular carcinoma (HCC): multiple underlying mechanisms. Sci China Life Sci. 2017;60:75–584.
Metadata
Title
Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy
Authors
Evangelista Sagnelli
Tommaso Stroffolini
Caterina Sagnelli
Mario Pirisi
Sergio Babudieri
Guido Colloredo
Maurizio Russello
Nicola Coppola
Giovanni Battista Gaeta
Bruno Cacopardo
Massimo De Luca
Piero Luigi Almasio
on behalf of EPACRON study group
Publication date
01-02-2018
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 1/2018
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-017-1101-5

Other articles of this Issue 1/2018

Infection 1/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.